Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.

Webinar on the latest developments in the analysis of single-cell data, including from transcriptomic and imaging technologies.

First closing of Series A round and onboarding of top biotech leaders to fuel growth in 2022

Support of discovery programs is essential to providing integrated drug development services. The key is to have the expertise to be able to tackle complex matrices along with any biomarker component.

The race is on for non-alcoholic steatohepatitis (NASH) drug development as the disease—which has no approved treatments—is rapidly growing in prevalence and is the fastest rising cause of liver transplantation in the United States.

Immunoprecipitation in combination with mass spectrometry is a powerful tool for studying disease-associated proteins

Presented by Covance Chief Scientific Officer Steve Anderson, Ph.D., and Covance Global Leader, Precision Medicine and Head, Biomarker Solution Center, Suso Platero, Ph.D., this webinar will address the spectrum of immunotherapy development considerations and their implications for drug developers.

NeuroQuest's blood-based biomarker test for early diagnosis of Alzheimer's disease exceeded U.S. Alzheimer's Association standards during recent pilot study in Australia. NeuroQuest has contracted with a major U.S. university to oversee collection and processing of 700 samples for their national clinical trial. The NeuroQuest blood test can potentially identify a pre-clinical stage of AD in a person years before the onset of noticeable symptoms, paving the way for new therapies and research.

Having already established itself as one of the leaders in its industry, Pathology Diagnostics is continuing to grow from strength to strength - evolving into a formidable organisation within its market space. Wanting to showcase its employee experti

Creodyne, LLC, announced today acquisition of intellectual property related to the design and implementation of a revolutionary nanoscale biosensing platform technology called the "Slider".

According to PBI, the major increase in the number of diagnosed cases of type 2 diabetes is the fastest-growing fraction in all age groups, and medical expenses for people with diabetes are more than two times higher than for people without diabetes.

Vice President of R&D Singled Out For Work In Seeking Clues to Heart-Disease Risk

Testing for the newly awarded contracts will begin as early as February 2011 and continue through the end of calendar 2011. PBI estimates the combined total revenue over the expected lives of these contracts at approximately $1.1 million.

Pacific Biomarkers has noted, with great interest, the publication of new studies suggesting that a simple urine test could help prevent cases of kidney failure.